 |
市場調查報告書
商品編碼
1983324
癌症精準醫療市場：按組成部分、診療路徑階段、技術、生物標記類型、檢體類型、最終用戶、癌症類型、報銷及獲取管道以及地區分類Oncology Precision Medicine Market, By Component, By Care Pathway Stage, By Technology, By Biomarker Type, By Sample Type, End User, By Cancer Type, By Reimbursement & Access Channel, By Geography |
||||||
價格
簡介目錄
預計到2026年，癌症精準醫療市場規模將達到1,905億美元，到2033年將達到3,665.3億美元。預計從2026年到2033年，該市場將以9.8%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 1905億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 9.80% | 2033年市場規模預測： | 3665.3億美元 |
全球癌症精準醫療市場代表著癌症治療領域的突破性模式轉移，從根本上改變了醫療專業人員進行診斷、選擇治療方法和患者照護管理的方式。腫瘤精準醫療利用先進的基因測序、生物標記識別、分子診斷和人工智慧技術，提供高度個人化的治療性介入根據患者的個別特徵和特定腫瘤特徵量身定做。
這種創新方法超越了傳統的、統一的調查方法，使臨床醫生能夠根據每位患者特有的惡性腫瘤的基因突變、蛋白質表現和細胞路徑，確定最佳治療方案。次世代定序(NGS)、液態生物檢體、藥物基因體學和伴隨診斷等最尖端科技的整合，正在加速標靶治療治療、免疫療法和聯合療法的開發，這些通訊協定展現出卓越的療效和更低的副作用。隨著全球醫療保健系統日益採用基於價值的醫療模式，並致力於在控制成本的同時改善患者預後，精準醫療正成為一項關鍵解決方案，有望提高治療反應率，最大限度地減少試驗錯處方箋，並最終提高包括肺癌、乳癌、結直腸癌、黑色素瘤和骨髓惡性腫瘤在內的多種癌症的生存率。
市場動態
全球癌症精準醫療市場受到多項強勁市場促進因素的推動，這些因素持續加速市場擴張，並促進全球醫療機構的普及應用。其中一個關鍵成長要素是基因測序技術成本的快速下降。這使得精準診斷在常規臨床實踐中更容易取得，也更經濟可行；同時，全球癌症發生率的上升也催生了對更有效、更個人化治療方案的迫切需求。
人工智慧、機器學習演算法和巨量資料分析等領域的技術進步，使醫療服務提供者能夠處理大量的基因組和臨床數據，從而實現更精準的治療預測和藥物選擇。政府舉措、監管支持以及公私合作對精準醫療研究的大量投資，進一步加速了市場成長，例如美國食品藥物管理局（FDA）等機構正在簡化伴隨診斷和標靶治療的核准流程。
然而，該市場面臨許多限制因素，尤其是在發展中地區建設醫療設施的高昂成本、各國法規結構的複雜性以及有效利用精準醫療技術所需的專業基礎設施和訓練有素的人員。此外，對資料隱私的擔憂、基因檢測相關的倫理考量以及某些醫療體系報銷政策的限制也阻礙了市場滲透。
儘管如此，將精準醫療融入常規臨床工作流程的潛力正在湧現出巨大的機遇，尤其是在其應用擴展到罕見癌症、液態生物檢體技術更加普及、與製藥公司在生物標記主導的藥物發現方面合作增多，以及醫療保健數位化加速發展、個性化療法成為全球腫瘤學標準治療方案的情況下。
本報告的主要特點
- 本報告對全球癌症精準醫療市場進行了詳細分析，包括預測期（2026-2033 年）的市場規模和複合年成長率，以 2025 年為基準年。
- 此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本文根據以下參數，介紹了全球癌症精準醫療市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
- 《全球癌症精準醫療市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球癌症精準醫療市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 法規環境
- 產品上市及核准
- PEST分析
- 波特五力分析
- 市場機遇
- 法規環境
- 主要進展
- 產業趨勢
第4章：全球癌症精準醫療市場：按組成部分分類（2021-2033 年）
- 治療藥物
- 診斷/檢查
- 資訊學與決策支持
- 服務
第5章：全球癌症精準醫療市場：依治療路徑階段分類（2021-2033 年）
- 風險評估和篩檢
- 診斷和腫瘤分類
- 治療方法方案
- 治療監測
- 復發監測/微小殘留病灶（MRD）
- 臨床試驗的註冊和匹配
第6章：全球癌症精準醫療市場：依技術分類（2021-2033 年）
- 基因組學
- 次世代定序（NGS）
- 轉錄組學
- 蛋白質體學/蛋白質生物標記物
- 細胞遺傳學和結構突變
- 表觀遺傳學
- 液態生物檢體技術
- 單細胞空間分析
第7章 全球癌症精準醫療市場：依生物標記類型分類（2021-2033 年）
- 基因生物標記
- 基因組特徵/全域標記
- 表現/蛋白質標記物
- 表觀遺傳生物標記
- MRD生物標記
第8章 全球癌症精準醫療市場：依檢體類型分類（2021-2033 年）
- 組織起源
- 血液來源（液態生物檢體）
- 其他生物體液
- 細胞學檢體
第9章 全球癌症精準醫療市場：依最終用戶分類（2021-2033 年）
- 醫院和癌症中心
- 診斷檢查室
- 臨床病理檢查室
- 分子和基因檢查室
- 學術和研究機構
- 製藥和生物技術公司
- CRO/臨床試驗網路
- 保險公司/HTA代理機構
第10章：全球癌症精準醫療市場：依癌症類型分類（2021-2033 年）
- 固體癌
- 肺、乳房、大腸、攝護腺、卵巢、黑色素瘤、胰臟、胃、頭頸部、肝臟、腎臟、腦部/中樞神經系統等。
- 骨髓惡性腫瘤
- 白血病、淋巴瘤、多發性骨髓瘤、MDS/MPN 等。
- 罕見癌症/腫瘤- 特異性片段
- 由腫瘤特異性生物標記定義的族群
第11章 全球癌症精準醫療市場：按報銷和取得管道分類（2021-2033 年）
- 公共保險報銷
- 私人保險報銷
- 自費/自籌資金
- 混合保險模式
- 病人支持/服務項目
- 透過臨床試驗進行的測試
第12章 全球癌症精準醫療市場：依地區分類（2021-2033年），市場規模
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第13章 競爭格局
- Hoffmann La Roche Ltd
- Novartis AG
- Pfizer Inc
- AstraZeneca plc
- Bristol Myers Squibb Company
- Merck &Co Inc
- Gilead Sciences Inc
- Illumina Inc
- Thermo Fisher Scientific Inc
- QIAGEN NV
- BioNTech SE
- Amgen Inc
- Foundation Medicine Inc
- Guardant Health
- Myriad Genetics Inc
第14章 分析師建議
- 機會
- 分析師意見
- Coherent Opportunity Map (COM)
第15章 參考文獻與分析方法
- 參考
- 分析方法
- 關於 Coherent Market Insights
簡介目錄
Product Code: CMI9316
Oncology Precision Medicine Market is estimated to be valued at USD 190.50 Bn in 2026 and is expected to reach USD 366.53 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 190.50 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 366.53 Bn |
The global oncology precision medicine market represents a revolutionary paradigm shift in cancer treatment, fundamentally transforming how healthcare providers approach diagnosis, treatment selection, and patient care management. Precision medicine in oncology leverages advanced genomic sequencing, biomarker identification, molecular diagnostics, and artificial intelligence to deliver highly personalized therapeutic interventions tailored to individual patient profiles and specific tumor characteristics.
This innovative approach moves beyond the traditional one-size-fits-all treatment methodology, enabling clinicians to identify optimal therapeutic pathways based on genetic mutations, protein expressions, and cellular pathways unique to each patient's malignancy. The integration of cutting-edge technologies such as next-generation sequencing (NGS), liquid biopsies, pharmacogenomics, and companion diagnostics has accelerated the development of targeted therapies, immunotherapies, and combination treatment protocols that demonstrate superior efficacy rates and reduced adverse effects. As healthcare systems worldwide increasingly adopt value-based care models and seek to improve patient outcomes while managing costs, precision medicine emerges as a critical solution that promises to enhance treatment response rates, minimize trial-and-error prescribing, and ultimately improve survival rates across various cancer types including lung, breast, colorectal, melanoma, and hematological malignancies.
Market Dynamics
The global oncology precision medicine market is propelled by several compelling drivers that continue to accelerate market expansion and adoption rates across healthcare institutions worldwide. The primary growth driver stems from the rapidly declining costs of genomic sequencing technologies, making precision diagnostics more accessible and economically viable for routine clinical implementation, while simultaneously increasing cancer incidence rates globally create an urgent demand for more effective, personalized treatment solutions.
Technological advancements in artificial intelligence, machine learning algorithms, and big data analytics enable healthcare providers to process vast amounts of genomic and clinical data, facilitating more accurate treatment predictions and drug selection processes. Government initiatives, regulatory support, and substantial investments in precision medicine research from both public and private sectors further accelerate market growth, with organizations like the U.S. FDA streamlining approval processes for companion diagnostics and targeted therapies.
However, the market faces significant restraints including high implementation costs for healthcare facilities, particularly in developing regions, complex regulatory frameworks that vary across different countries, and the need for specialized infrastructure and trained personnel to effectively utilize precision medicine technologies. Data privacy concerns, ethical considerations surrounding genetic testing, and limited reimbursement policies in certain healthcare systems also impede market penetration.
Nevertheless, substantial opportunities emerge from expanding applications in rare cancers, growing adoption of liquid biopsy technologies, increasing pharmaceutical partnerships for biomarker-driven drug development, and the potential for precision medicine integration into routine clinical workflows, particularly as healthcare digitization accelerates and personalized treatment becomes the standard of care across oncology practices globally.
Key Features of the Study
- This report provides in-depth analysis of the global oncology precision medicine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global oncology precision medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann La Roche Ltd, Novartis AG, Pfizer Inc, AstraZeneca plc, Bristol Myers Squibb Company, Merck & Co Inc, Gilead Sciences Inc, Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN NV, BioNTech SE, Amgen Inc, Foundation Medicine Inc, Guardant Health, and Myriad Genetics Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global oncology precision medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology precision medicine market
Market Segmentation
- Component Insights (Revenue, USD Bn, 2021 - 2033)
- Therapeutics
- Targeted therapies
- Targeted biologics
- Precision immuno-oncology
- Cell & gene therapies
- Radiotheranostics / targeted radionuclide therapies
- Combination regimens
- Diagnostics / Testing
- Companion diagnostics (CDx)
- Complementary diagnostics
- Comprehensive genomic profiling (CGP) panels
- Minimal residual disease (MRD) testing
- Pharmacogenomics (PGx) relevant to oncology regimens
- Informatics & Decision Support
- Clinical decision support (CDS) / treatment matching engines
- Variant interpretation & annotation platforms
- Molecular tumor board (MTB) enablement software
- Data integration (EHR/LIS/omics) & interoperability tools
- Services
- Sample logistics, biobanking, and pre-analytics services
- Bioinformatics services (pipeline, interpretation, reporting)
- Clinical trial matching services
- Real-world evidence (RWE) and outcomes analytics
- Contract research / companion diagnostic development services
- Care Pathway Stage (Revenue, USD Bn, 2021 - 2033)
- Risk assessment & screening
- Diagnosis & tumor classification
- Therapy selection
- Treatment monitoring
- Response monitoring
- Resistance emergence detection
- Dose/therapy optimization
- Recurrence surveillance / MRD
- Clinical trial enrolment & matching
- Technology (Revenue, USD Bn, 2021 - 2033)
- Genomics
- Next-generation sequencing (NGS)
- Targeted panels
- Whole exome sequencing (WES)
- Whole genome sequencing (WGS)
- PCR / qPCR / ddPCR
- Sanger sequencing (confirmatory)
- Transcriptomics
- RNA sequencing (RNA-seq)
- Gene expression profiling / signatures
- Proteomics / Protein biomarkers
- Immunohistochemistry (IHC)
- Mass spectrometry-based proteomics (select settings)
- Cytogenetics & Structural Variation
- FISH
- Karyotyping (certain hematologic cancers)
- Epigenetics
- DNA methylation profiling (select tumors)
- Liquid biopsy technologies
- ctDNA / cfDNA
- CTCs
- Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
- Single-cell sequencing (scRNA/scDNA)
- Spatial transcriptomics / multiplex imaging
- Biomarker Type (Revenue, USD Bn, 2021 - 2033)
- Genetic biomarkers
- Single nucleotide variants (SNVs)
- Indels
- Copy number variations (CNVs)
- Gene fusions / rearrangements
- Germline variants (hereditary cancer)
- Genomic signatures / global markers
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Homologous recombination deficiency (HRD)
- Expression / protein markers
- Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic biomarkers
- Methylation signatures
- MRD biomarkers
- Personalized tumor-informed MRD
- Tumor-naive MRD panels
- Sample Type (Revenue, USD Bn, 2021 - 2033)
- Tissue-based
- FFPE tissue
- Fresh frozen tissue
- Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
- Plasma (ctDNA/cfDNA)
- Whole blood (CTCs, RNA)
- Other biofluids
- Urine, saliva, CSF (indication-dependent)
- Cytology samples
- FNA, smears (select workflows)
- End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals & cancer centers
- Diagnostic laboratories
- Clinical pathology labs
- Molecular/genetic labs
- Academic & research institutes
- Pharmaceutical & biotech companies
- CROs / clinical trial networks
- Payers / HTA bodies
- Cancer Type (Revenue, USD Bn, 2021 - 2033)
- Solid tumors
- Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic malignancies
- Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare cancers / tumor-agnostic segments
- Tumor-agnostic biomarker-defined populations
- Reimbursement & Access Channel (Revenue, USD Bn, 2021 - 2033)
- Public reimbursement
- Private reimbursement
- Out-of-pocket / self-pay
- Hybrid coverage models
- Patient assistance / access programs
- Clinical trial-funded testing
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hoffmann La Roche Ltd
- Novartis AG
- Pfizer Inc
- AstraZeneca plc
- Bristol Myers Squibb Company
- Merck & Co Inc
- Gilead Sciences Inc
- Illumina Inc
- Thermo Fisher Scientific Inc
- QIAGEN NV
- BioNTech SE
- Amgen Inc
- Foundation Medicine Inc
- Guardant Health
- Myriad Genetics Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Oncology Precision Medicine Market, By Component
- Global Oncology Precision Medicine Market, By Care Pathway Stage
- Global Oncology Precision Medicine Market, By Technology
- Global Oncology Precision Medicine Market, By Biomarker Type
- Global Oncology Precision Medicine Market, By Sample Type
- Global Oncology Precision Medicine Market, By End User
- Global Oncology Precision Medicine Market, By Cancer Type
- Global Oncology Precision Medicine Market, By Reimbursement & Access Channel
- Global Oncology Precision Medicine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Oncology Precision Medicine Market, By Component, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted therapies
- Targeted biologics
- Precision immuno-oncology
- Cell & gene therapies
- Radiotheranostics / targeted radionuclide therapies
- Combination regimens
- Diagnostics / Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Companion diagnostics (CDx)
- Complementary diagnostics
- Comprehensive genomic profiling (CGP) panels
- Minimal residual disease (MRD) testing
- Pharmacogenomics (PGx) relevant to oncology regimens
- Informatics & Decision Support
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical decision support (CDS) / treatment matching engines
- Variant interpretation & annotation platforms
- Molecular tumor board (MTB) enablement software
- Data integration (EHR/LIS/omics) & interoperability tools
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Sample logistics, biobanking, and pre-analytics services
- Bioinformatics services (pipeline, interpretation, reporting)
- Clinical trial matching services
- Real-world evidence (RWE) and outcomes analytics
- Contract research / companion diagnostic development services
5. Global Oncology Precision Medicine Market, By Care Pathway Stage, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Risk Assessment & Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnosis & Tumor Classification
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Therapy Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Treatment Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Response Monitoring
- Resistance Emergence Detection
- Dose/Therapy Optimization
- Recurrence Surveillance / MRD
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical Trial Enrolment & Matching
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Oncology Precision Medicine Market, By Technology, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Genomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Next-generation sequencing (NGS)
- Targeted panels
- Whole exome sequencing (WES)
- Whole genome sequencing (WGS)
- PCR / qPCR / ddPCR
- Sanger sequencing (confirmatory)
- Transcriptomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- RNA sequencing (RNA-seq)
- Gene expression profiling / signatures
- Proteomics / Protein biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunohistochemistry (IHC)
- Mass spectrometry-based proteomics (select settings)
- Cytogenetics & Structural Variation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FISH
- Karyotyping (certain hematologic cancers)
- Epigenetics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- DNA methylation profiling (select tumors)
- Liquid biopsy technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- ctDNA / cfDNA
- CTCs
- Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Single-cell sequencing (scRNA/scDNA)
- Spatial transcriptomics / multiplex imaging
7. Global Oncology Precision Medicine Market, By Biomarker Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Genetic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Single nucleotide variants (SNVs)
- Indels
- Copy number variations (CNVs)
- Gene fusions / rearrangements
- Germline variants (hereditary cancer)
- Genomic Signatures / Global Markers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Homologous recombination deficiency (HRD)
- Expression / Protein Markers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Methylation signatures
- MRD Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Personalized tumor-informed MRD
- Tumor-naive MRD panels
8. Global Oncology Precision Medicine Market, By Sample Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tissue-based
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FFPE tissue
- Fresh frozen tissue
- Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Plasma (ctDNA/cfDNA)
- Whole blood (CTCs, RNA)
- Other Biofluids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Urine, saliva, CSF (indication-dependent)
- Cytology Samples
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FNA, Smears (Select Workflows)
9. Global Oncology Precision Medicine Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals & cancer centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnostic laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical pathology labs
- Molecular/genetic labs
- Academic & research institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pharmaceutical & biotech companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CROs / clinical trial networks
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Payers / HTA bodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
10. Global Oncology Precision Medicine Market, By Cancer Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Solid Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare Cancers / Tumor-agnostic Segments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tumor-agnostic biomarker-defined populations
11. Global Oncology Precision Medicine Market, By Reimbursement & Access Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Public Reimbursement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Private Reimbursement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Out-of-pocket / Self-pay
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hybrid coverage models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Patient Assistance / Access Programs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical trial-funded Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
12. Global Oncology Precision Medicine Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Hoffmann La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Illumina Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- QIAGEN NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Foundation Medicine Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Guardant Health
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Myriad Genetics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
